

Reference: FOI.ICB-2324/043

Subject: Ophthalmology Services

I can confirm that the ICB does hold some of the information requested; please see responses below:

QUESTION	RESPONSE
1. Which of your local trusts is delivering hydroxychloroquine retinal screening. If private providers then please advise which providers.	The ICB does not hold this information. We advise you to contact the trusts directly; University Hospitals Bristol and Weston NHS Foundation Trust (UHBW) and North Bristol NHS Trust (NBT):
2. What is their waiting list period for this?	https://www.nbt.nhs.uk/about-us/information-governance/freedom-information/request-information / foi@nbt.nhs.uk https://www.uhbw.nhs.uk/p/how-we-use-your-data/freedom-of-information-foi-requests / FreedomOfInfo@uhbw.nhs.uk
3. How many patients have had their screening completed?	There were 39,531 outpatient attendances for retinal screening in 2022/23, however with diagnosis code not recorded for this data, we do not know how many of these are for hydroxychloroquine.
4. How many patients in total require screening?	See question 1

<p>5. How many screening clinics are performed weekly at the trusts / private providers, offering this. Please state trust name and the number of clinics.</p>	<p>See question 1</p>
<p>6. If private providers are used what are the agreed tariffs for each aspect of the screening.</p>	<p>The ICB does not hold this information.</p>
<p>7. How many incidents / SIs have been recorded over the last 3 years relating to hydroxychloroquine screening (breakdown per year please)</p>	<p>Zero</p>
<p>8. What is the current Glaucoma patient waiting list at each Trust and private provider you manage and contract.</p>	<p>For trusts see question 1. Independent Sector (IS) providers: New Medica 489 Spa Medica 216</p>
<p>9. How many incidents, near misses or SIs have been recorded relating to glaucoma at each Trust or provider over the last 3 years (breakdown per year please)</p>	<p>Trusts: 2020: 2 2021: 3 2022: 4 2023: 1 IS providers: We do not hold this information</p>

<p>10. Are all glaucoma patients risk stratified at each provider / trust. If so what method and categories are they using.</p>	<p>See question 1</p>
<p>11. How many new glaucoma patients are waiting to be seen.</p>	<p>For trusts please see question 1 IS providers: 705</p>
<p>12. If private providers are used what are the agreed tariffs.</p>	<p>IS providers: As per NHS Payment System (NHSPS)</p>
<p>13. How many stable AMD patients are seen at each Trust for monitoring. Clarification received 25/04/23: AMD is short for Age related macular degeneration.</p>	<p>332 patients had ophthalmology outpatient attendances in 2022/23 who had also had an inpatient attendance where AMD was a diagnosis. This may include patients who have ophthalmology attendances for different reasons and also exclude patients who may have monitoring for AMD but have not had an inpatient admission</p>
<p>14. What is the waiting list at each provider for AMD patients that are stable. Clarification received 25/04/23: AMD is short for Age related macular degeneration.</p>	<p>See question 1</p>
<p>15. How many incidents / SIs have been recorded over the last 3 years relating to AMD care at each Trust (breakdown per year please) Clarification received 25/04/23: AMD is short for Age related macular degeneration.</p>	<p>2022: 2</p>

16. If private providers are used what are the agreed tariffs.	See question 12
17. For all private providers used for ophthalmology can you declare which consultants / Doctors have a financial interest with them that also work for the NHS trusts.	See question 1

The information provided in this response is accurate as of 19 May 2023 and has been approved for release by Sarah Truelove, Deputy Chief Executive and Chief Finance Officer for NHS Bristol, North Somerset and South Gloucestershire ICB.